Seagen Inc (SGEN)

151.11 +1.02  +0.68% NASDAQ Feb 26, 20:00 USD
View Full Chart
Price Chart
View All SGEN News

News

View All Events

Events

Date Type Description
04/30/2021 Earnings Seattle Genetics Inc First Quarter Earnings Results for 2021
04/30/2021 Misc Seattle Genetics Inc First Quarter Earnings Conference Call for 2021
02/11/2021 Earnings Seagen Inc Fourth Quarter Earnings Result for 2020
02/11/2021 16:30 EST Misc Seagen Inc Fourth Quarter Earnings Conference Call for 2020
10/29/2020 16:30 EDT Misc Seagen Inc Third Quarter Earnings Conference Call for 2020
10/29/2020 Earnings Seagen Inc Third Quarter Earnings Result for 2020
07/30/2020 16:30 EDT Misc Seattle Genetics Inc Second Quarter Earnings Conference Call for 2020
07/30/2020 Earnings Seattle Genetics Inc Second Quarter Earnings Result for 2020
05/15/2020 11:00 PDT Misc Seattle Genetics Inc Annual General Meeting for 2019
04/30/2020 16:30 EDT Misc Seattle Genetics Inc First Quarter Earnings Conference Call for 2020
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.seagen.com
  • Investor Relations URL: http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-IRHome
  • HQ State/Province: Washington
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Apr. 30, 2021
  • Last Earnings Release: Feb. 11, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Top Fund Holders

Symbol Name Weighting
HQL Tekla Life Sciences Investors 4.64%
HQH Tekla Healthcare Investors 4.13%
BBH VanEck Vectors Biotech ETF 3.53%
POAGX PRIMECAP Odyssey Aggressive Growth 2.83%
BMEZ BlackRock Health Sciences Trust II 2.74%
IBB iShares Nasdaq Biotechnology ETF 2.22%
POGRX PRIMECAP Odyssey Growth 2.14%
BME BlackRock Health Sciences 2.11%
SHISX BlackRock Health Sciences Opps Svc 1.97%
VHCOX Vanguard Capital Opportunity Inv 1.86%
JLGZX JPMorgan Large Cap Growth R2 1.80%
THISX T. Rowe Price Health Sciences I 1.29%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.